ATE535245T1 - Verwendung von mehrfach ungesättigten ketonen zur behandlung der psoriasis - Google Patents

Verwendung von mehrfach ungesättigten ketonen zur behandlung der psoriasis

Info

Publication number
ATE535245T1
ATE535245T1 AT03704739T AT03704739T ATE535245T1 AT E535245 T1 ATE535245 T1 AT E535245T1 AT 03704739 T AT03704739 T AT 03704739T AT 03704739 T AT03704739 T AT 03704739T AT E535245 T1 ATE535245 T1 AT E535245T1
Authority
AT
Austria
Prior art keywords
group
psoriasis
treat psoriasis
polyunsaturated ketones
hydrocarbon group
Prior art date
Application number
AT03704739T
Other languages
English (en)
Inventor
Berit Johansen
Marit Anthonsen
Wenche Sjursen
Anne Kristen Holmeide
Lars Skattebol
Original Assignee
Avexxin As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avexxin As filed Critical Avexxin As
Application granted granted Critical
Publication of ATE535245T1 publication Critical patent/ATE535245T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03704739T 2002-01-29 2003-01-29 Verwendung von mehrfach ungesättigten ketonen zur behandlung der psoriasis ATE535245T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202002.2A GB0202002D0 (en) 2002-01-29 2002-01-29 Use
PCT/GB2003/000364 WO2003063878A1 (en) 2002-01-29 2003-01-29 Use of polyunsaturated ketones for the treatment of psoriasis

Publications (1)

Publication Number Publication Date
ATE535245T1 true ATE535245T1 (de) 2011-12-15

Family

ID=9929945

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03704739T ATE535245T1 (de) 2002-01-29 2003-01-29 Verwendung von mehrfach ungesättigten ketonen zur behandlung der psoriasis

Country Status (14)

Country Link
US (4) US7687543B2 (de)
EP (1) EP1469859B1 (de)
JP (1) JP4608214B2 (de)
KR (1) KR100874505B1 (de)
CN (2) CN1678323A (de)
AT (1) ATE535245T1 (de)
AU (1) AU2003206999B2 (de)
CA (1) CA2473687C (de)
DK (1) DK1469859T3 (de)
ES (1) ES2378303T3 (de)
GB (1) GB0202002D0 (de)
NO (1) NO334413B1 (de)
PT (1) PT1469859E (de)
WO (1) WO2003063878A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2248798A1 (de) * 2009-05-08 2010-11-10 Pronova BioPharma Norge AS Neue Lipidverbindungen
GB0909643D0 (en) * 2009-06-04 2009-07-22 Avexxin As Glomerulonephritis treatment
CA2782797C (en) * 2009-10-02 2018-08-07 Avexxin As Anti inflammatory 2-oxothiazoles and 2 -oxooxazoles
GB201014633D0 (en) 2010-09-02 2010-10-13 Avexxin As Rheumatoid arthritis treatment
SG10201509127YA (en) 2010-11-05 2015-12-30 Pronova Biopharma Norge As Methods of treatment using lipid compounds
GB201205394D0 (en) 2012-03-27 2012-05-09 Adlens Ltd Improvements in or relating to deformable non-round membrane assemblies
GB201221329D0 (en) 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
JP6371312B2 (ja) 2013-01-29 2018-08-08 アヴェクシン エーエス 坑炎症および抗腫瘍２−オキソチアゾール化合物ならびに２−オキソチオフェン化合物
KR102213143B1 (ko) 2013-02-28 2021-02-08 바스프 에이에스 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법
GB201313238D0 (en) 2013-07-24 2013-09-04 Avexxin As Process for the preparation of a polyunsaturated ketone compound
GB201409363D0 (en) * 2014-05-27 2014-07-09 Avexxin As Skin cancer treatment
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
GB201501144D0 (en) 2015-01-23 2015-03-11 Avexxin As Process for the preparation of a polyunsaturated ketone compound
CN107530306A (zh) 2015-04-28 2018-01-02 普罗诺瓦生物医药挪威公司 结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
US20190209585A1 (en) * 2016-06-03 2019-07-11 Avexxin As Combination therapy comprising a polyunsaturated ketone and a secosteroid
GB201609735D0 (en) * 2016-06-03 2016-07-20 Avexxin As Combination therapy
EP3463473A1 (de) * 2016-06-03 2019-04-10 Avexxin AS Kombinationstherapie mit einem mehrfach ungesättigten keton und einem kortikosteroid
WO2017207819A1 (en) * 2016-06-03 2017-12-07 Avexxin As Combination therapy comprising a polyunsaturated ketone and a calcineurin inhibitor
US11351127B2 (en) 2016-09-21 2022-06-07 Avexxin As Pharmaceutical composition
CN110996931B (zh) * 2017-06-16 2023-12-15 埃维克辛公司 用于治疗纤维化疾病的组合物和方法
ES2996688T3 (en) 2017-12-06 2025-02-13 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
GB201807892D0 (en) 2018-05-15 2018-06-27 Avexxin As Processes in the preparation of polyunsaturated ketone compounds
GB202020843D0 (en) 2020-12-31 2021-02-17 Coegin Pharma Ab Actinic keratosis treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09268153A (ja) 1996-04-02 1997-10-14 Sagami Chem Res Center トリフルオロメチルケトン誘導体及びホスホリパーゼａ２阻害剤
WO1999015129A2 (en) * 1997-09-23 1999-04-01 Bristol-Myers Squibb Company SELECTIVE cPLA2 INHIBITORS
JPH11199493A (ja) * 1997-11-13 1999-07-27 Nof Corp 皮膚外用剤組成物
US7605149B1 (en) * 1998-07-13 2009-10-20 University Of South Florida Modulation of the phospholipase A2 pathway as a therapeutic
US20020165119A1 (en) 2001-01-31 2002-11-07 Alan Leff Method of treating inflammatory conditions by inhibiting cytosolic phospholipase A2
EP1243524A3 (de) * 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmazeutisches Kit fÜr sauerstoffempfindliche Medikamente
US20040111957A1 (en) * 2002-12-13 2004-06-17 Filippini Brian B. Water blended fuel composition

Also Published As

Publication number Publication date
US9375409B2 (en) 2016-06-28
US20130324613A1 (en) 2013-12-05
US7687543B2 (en) 2010-03-30
US20100152293A1 (en) 2010-06-17
JP4608214B2 (ja) 2011-01-12
US20150202165A1 (en) 2015-07-23
EP1469859B1 (de) 2011-11-30
US8524776B2 (en) 2013-09-03
GB0202002D0 (en) 2002-03-13
ES2378303T3 (es) 2012-04-11
NO20043548L (no) 2004-08-25
KR20040089127A (ko) 2004-10-20
CN1678323A (zh) 2005-10-05
CA2473687C (en) 2011-04-12
EP1469859A1 (de) 2004-10-27
WO2003063878A1 (en) 2003-08-07
KR100874505B1 (ko) 2008-12-18
DK1469859T3 (da) 2012-03-19
JP2005518419A (ja) 2005-06-23
US20050165116A1 (en) 2005-07-28
US8865768B2 (en) 2014-10-21
PT1469859E (pt) 2012-03-06
CN101849929A (zh) 2010-10-06
NO334413B1 (no) 2014-02-24
AU2003206999B2 (en) 2007-12-13
CA2473687A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
ATE535245T1 (de) Verwendung von mehrfach ungesättigten ketonen zur behandlung der psoriasis
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
ATE497778T1 (de) Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
BR0213100A (pt) Combinações para o tratamento de distúrbios imuniinflamatórios
ATE452884T1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
ATE425752T1 (de) Verwendung von pipamperon und einem sndri, snri oder ssri zur behandlung von stimmungs- oder angststírungen
DE602006020775D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
DE60011794D1 (de) Verwendung von docetaxel für die behandlung von hepatozelluläre krebs
ATE415965T1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
SE0301883D0 (sv) New use II
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE486612T1 (de) Verfahren zur behandlung von diabetes typ 2
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
MXPA04011018A (es) Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias.
SE0301884D0 (sv) New use III
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE361085T1 (de) Verwendung einer zusätzlich fermentierten getreideschlempe zur vorbeugung und/oder behandlung erhähter blutzucker-werte
ATE409469T1 (de) Verwendung von 2,2,3,3, tetramethylcyclopropane carbonsäure derivaten zur behandlung von psychiatrischen störungen